


Cell Reports, Volume 30


Supplemental Information

Virus-Mediated Suppression of the Antigen Presentation Molecule MR1


Brian P. McSharry, Carolyn Samer, Hamish E.G. McWilliam, Caroline L. Ashley, Michael B. Yee, Megan Steain, Ligong Liu, David P. Fairlie, Paul R. Kinchington, James McCluskey, Allison Abendroth, Jose A. Villadangos, Jamie Rossjohn, and Barry Slobedman




Supp Fig 1 : Treatment of HFFs with ligand drives surface MR1, related to Fig 1A. HFFs were left untreated or treated with Ac-6-FP (5 μ M) for 16 h before staining for MR1, MHC I or isotype control (grey) as indicated. Data is representative of at least 3 independent experiments.




Supp Fig 2 : Ad infection inhibits MHC I but not MR1 surface expression, related to Fig 1A. 293 cells were infected with wild type Ad or $\Delta E3/19K$ at an MOI of 10 with Ac-6-FP (5 μM) added at 6 h p.i. before staining for surface MR1, MHC I or isotype control (grey) as indicated at 24 h p.i. Data is representative of 2 independent experiments.




Supp Fig 3 : HSV-1 infection inhibits surface MR1 surface expression at 6 h p.i., related to Fig 1C. ARPE-19 MR1 were mock or HSV-1 infected before staining at 6 h p.i. for surface MR1, MHC I or isotype control (grey) as indicated. Fold change in MFI relative to mock infected cells is graphed. Statistical significance was calculated by paired Student's *t*-test * $p < 0.05$, (n=4)




Supp Fig 4: Ligand binding blocks HSV-1 dependent targeting of surface MR1, related to Fig 2. HFFs overexpressing MR1 were mock or HSV-1 infected in parallel. Cells were either treated with Ac-6-FP (5 μ M) for (A) 24 h prior to infection (pre) or (B) at 6 h post infection (post) before staining for surface MR1, MHC I or isotype control (grey) as indicated at 24 h p.i. Data is representative of 2 independent experiments.




Supp Fig 5. HSV-1 can inhibit MR1-GFP surface expression in a ligand dependent manner, related to Fig 2. ARPE-19 MR1-GFP were mock or HSV-1 infected in parallel. Cells were either treated the Ac-6-FP (5 μ M) for 24 h prior to infection (pre) or at 14 h post infection (post) before (A) staining for surface MR1, MHC I at 18 h p.i. and analysis by flow cytometry. (B) Fold change relative to mock infected cells is graphed. Statistical significance was calculated by ANOVA * $p < 0.05$, ** $p < 0.005$, *** $p < 0.0005$, **** $p < 0.0001$ (n=4) (C) Cell lysates from mock or HSV-1 infected ARPE-19 MR1 cells treated with Ac-6-FP (5 μ M) for 24 h prior to infection (pre) or at 14 h p.i. (post) were harvested at 18 h p.i. and immunoblotted for GFP and GAPDH. Data is representative of 2 independent experiments.



Supp Fig 6: TCR-mediated activation of Jurkat MAIT cells by ligand treatment and HSV-1 infection, related to Fig 4. (A) Mock or HSV-1 infected HFFs were treated with 5-OP-RU (10 μ M) at 14 h p.i. before staining for surface MR1 or isotype control (grey) at 18 h p.i. (B) CD69 expression on Jurkat MAIT (JM) cells incubated with mock or HSV-1 infected cells treated with *E. coli* or 5-OP-RU before blocking with anti-MR1 or isotype control as indicated (C) Fold change in CD69 expression on JM left untreated or treated with 5-OP-RU is graphed. Statistical significance was calculated by paired Student's *t*-test *** $p < 0.001$, (n=6)




Supp Fig 7: Late viral gene expression is not blocked by proteasomal inhibition, related to Fig 5. ARPE-19 cells were infected with HSV-1 Strain F (MOI=5) or mock infected in parallel, and stained for the viral protein gD or isotype control (grey) at 18 h p.i. Cells were treated with MG132 (5 μ M at 0 h p.i.) or DMSO, or left untreated as indicated.



Supp Fig 8. HSV-1 Us3 expression downregulates surface MR1, related to Fig 7A.

293T cells transduced with lentivirus expressing HSV-1 Us3 were treated with Ac-6-FP (5 μ M) for 6 h prior to staining for surface MR1, analysis by flow cytometry, with gating on GFP expression to identify Us3-expressing GFP⁺ cells. Fold change relative to GFP⁻ cells is graphed. Statistical significance was calculated by paired Student's *t*-test ** $p < 0.005$, *** $p < 0.0005$, (n=3).



Supp Fig 9: Construction of HSV-1 Us3 mutant, related to STAR methods. HSV-1 KOS Us3 coding sequence was inserted downstream of eGFP in pEGFP-C1 plasmid before digesting with BglIII and BamHI to collapse Us3. Mutation introduced into parental virus through homologous recombination to generate Δ Us3.